Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
AIMT Aimmune $23.70 0.73 (3.18%) , AZN AstraZeneca $40.95 0.515 (1.27%) … 04:55 02/23/19 02/23 04:55 02/23/19 04:55 Conference/Events	The American Academy of Asthma, Allergy & Immunology to hold annual meeting » AAAAI Annual Meeting 2019… AIMT Aimmune $23.70 0.73 (3.18%) AZN AstraZeneca $40.95 0.515 (1.27%) TEVA Teva $17.28 0.03 (0.17%) NVS Novartis $90.77 0.26 (0.29%) DNA Bought by RHHBY $0.00 (0.00%) SHPG Shire $0.00 (0.00%) REGN Regeneron $422.43 3.77 (0.90%) SNY Sanofi $41.20 -0.13 (-0.31%) ALK Alaska Air $62.35 -0.48 (-0.76%) ABT Abbott $76.40 1.26 (1.68%) CVS CVS Health $62.00 -0.33 (-0.53%) KALV KalVista $20.74 -0.04 (-0.19%) BCRX BioCryst $8.99 0.32 (3.69%) OPTN Optinose $7.31 0.02 (0.27%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Feb 27 Feb 28 Feb 28 Feb 04 Mar 04 Mar 04 Mar 07 Mar 11 Mar 11 Mar 12 Mar 18 Mar 19 Mar 22 Mar 28 Apr 13 May 18 May

Yesterday
BMY Bristol-Myers $50.99 0.84 (1.68%) , CELG Celgene $89.15 0.54 (0.61%) 16:52 02/22/19 02/22 16:52 02/22/19 16:52 Hot Stocks	Bristol-Myers files proxy statement in connection with proposed Celgene merger » Bristol-Myers Squibb… Bristol-Myers Squibb Company (BMY) announced that it has filed definitive proxy materials with the SEC in connection with the company's pending merger with Celgene Corporation (CELG). Bristol-Myers Squibb will commence mailing the joint proxy statement / prospectus to its stockholders on or about February 22. The Bristol-Myers Squibb Special Meeting of Stockholders is scheduled to take place on April 12. All stockholders of record of Bristol-Myers Squibb common stock as of the close of business on March 1 will be entitled to vote their shares either in person or by proxy at the stockholder meeting. The Bristol-Myers Squibb board believes this combination is in the best interests of the company and its stockholders, and recommends that stockholders vote "FOR" the approval of the issuance of shares of Bristol-Myers Squibb common stock in the merger, as well as all other proposals included on the enclosed WHITE proxy card. As previously announced on January 3, the combination of Bristol-Myers Squibb and Celgene will create a leading focused specialty biopharma company that is well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. BMY Bristol-Myers $50.99 0.84 (1.68%) CELG Celgene $89.15 0.54 (0.61%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb 26 Feb 28 Feb 18 May 20 May 28 May
ABBV AbbVie $79.47 0.71 (0.90%) , AZN AstraZeneca $40.78 0.345 (0.85%) … 15:14 02/22/19 02/22 15:14 02/22/19 15:14 Conference/Events	Senate Finance Committee to hold a hearing » The Committee holds a… The Committee holds a hearing entitled, "Drug Pricing in America: A Prescription for Change--Part 1I" with Richard Gonzalez, CEO of AbbVie, Pascal Soriot, CEO of AstraZeneca, Giovanni Caforio, CEO of Bristol-Myers Squibb; Jennifer Taubert, EVP of Janssen Pharmaceuticals (Johnson & Johnson), Albert Bourla, CEO of Pfizer, Olivier Brandicourt, CEO of Sanofi and Kenneth Frazier, CEO of Merck on February 26 at 10:15 am. Webcast Link ABBV AbbVie $79.47 0.71 (0.90%) AZN AstraZeneca $40.78 0.345 (0.85%) BMY Bristol-Myers $50.75 0.6 (1.20%) JNJ Johnson & Johnson $136.22 0.82 (0.61%) MRK Merck $80.39 0.57 (0.71%) PFE Pfizer $42.91 0.77 (1.83%) SNY Sanofi $41.10 -0.23 (-0.56%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb 22 Feb 25 Feb 25 Feb 27 Feb 28 Feb 04 Mar 06 Mar 07 Mar 11 Mar 22 Mar 11 Apr 28 Apr 18 May 20 May 17 Jun
AVEO Aveo Pharmaceuticals $0.62 0.0006 (0.10%) , BMY Bristol-Myers $50.47 0.32 (0.64%) … 10:25 02/22/19 02/22 10:25 02/22/19 10:25 Conference/Events	Piper Jaffray biotech analysts to hold an analyst/industry conference call » Biotech Analysts, along… Biotech Analysts, along with a Key Opinion Leader (KOL) in the genitourinary oncology sector, discuss the evolving treatment landscapes in Urothelial Bladder Cancer (UBC) and Renal Cell Carcinoma (RCC) on an Analyst/Industry conference call to be held on February 22 at 11 am. AVEO Aveo Pharmaceuticals $0.62 0.0006 (0.10%) BMY Bristol-Myers $50.47 0.32 (0.64%) EXEL Exelixis $21.28 0.06 (0.28%) IMMU Immunomedics $14.34 0.01 (0.07%) JNJ Johnson & Johnson $135.83 0.43 (0.32%) MRK Merck $80.55 0.73 (0.91%) NKTR Nektar $40.10 -0.16 (-0.40%) PFE Pfizer $42.89 0.75 (1.78%) SGEN Seattle Genetics $69.99 0.74 (1.07%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb 25 Feb 25 Feb 25 Feb 27 Feb 28 Feb 06 Mar 11 Apr 18 May 20 May 17 Jun
AVEO Aveo Pharmaceuticals $0.62 -0.0047 (-0.75%) , BMY Bristol-Myers $50.15 -1.14 (-2.22%) … 08:57 02/22/19 02/22 08:57 02/22/19 08:57 Conference/Events	Piper Jaffray biotech analysts to hold an analyst/industry conference call » Biotech Analysts, along… Biotech Analysts, along with a Key Opinion Leader (KOL) in the genitourinary oncology sector, discuss the evolving treatment landscapes in Urothelial Bladder Cancer (UBC) and Renal Cell Carcinoma (RCC) on an Analyst/Industry conference call to be held on February 22 at 11 am. AVEO Aveo Pharmaceuticals $0.62 -0.0047 (-0.75%) BMY Bristol-Myers $50.15 -1.14 (-2.22%) EXEL Exelixis $21.22 (0.00%) IMMU Immunomedics $14.33 -0.03 (-0.21%) JNJ Johnson & Johnson $135.40 -0.91 (-0.67%) MRK Merck $79.82 0.38 (0.48%) NKTR Nektar $40.26 -2.76 (-6.42%) PFE Pfizer $42.14 -0.07 (-0.17%) SGEN Seattle Genetics $69.25 -0.53 (-0.76%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	25 Feb 25 Feb 25 Feb 27 Feb 28 Feb 06 Mar 11 Apr 18 May 20 May 17 Jun

GE General Electric $10.03 -0.07 (-0.69%) , LLY Eli Lilly $122.72 0.05 (0.04%) … 08:55 02/22/19 02/22 08:55 02/22/19 08:55 Options	Notable open interest changes for February 22nd » Thursday's total… Thursday's total option volume of 16.0 million contracts resulted in net open interest growth of 2.86 million calls and 3.34 million puts. General Electric (GE), Eli Lilly (LLY), Tesla (TSLA) and Elanco Animal Health (ELAN) saw the greatest growth. Top five new positions opened include 100k General Electric (GE) 3/8 weekly 9 puts, 60k Eli Lilly (LLY) Mar-19 150 calls, 59k Eli Lilly (LLY) Mar-19 150 puts, 26k Elanco Animal Health (ELAN) Mar-19 40 puts and 26k Elanco Animal Health (ELAN) Mar-19 40 calls. GE General Electric $10.03 -0.07 (-0.69%) LLY Eli Lilly $122.72 0.05 (0.04%) TSLA Tesla $291.18 -11.33 (-3.75%) ELAN Elanco $29.07 -0.29 (-0.99%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	25 Feb 27 Feb 18 Mar 19 Mar 18 May
AIMT Aimmune $22.97 -0.23 (-0.99%) , AZN AstraZeneca $40.44 -0.105 (-0.26%) … 08:35 02/22/19 02/22 08:35 02/22/19 08:35 Conference/Events	The American Academy of Asthma, Allergy & Immunology to hold annual meeting » AAAAI Annual Meeting 2019… AAAAI Annual Meeting 2019 will be held in San Francisco on February 22-25. AIMT Aimmune $22.97 -0.23 (-0.99%) AZN AstraZeneca $40.44 -0.105 (-0.26%) TEVA Teva $17.25 -0.15 (-0.86%) NVS Novartis $90.51 -0.26 (-0.29%) DNA Bought by RHHBY $0.00 (0.00%) SHPG Shire $0.00 (0.00%) REGN Regeneron $418.66 -3.9 (-0.92%) SNY Sanofi $41.33 -0.74 (-1.76%) ALK Alaska Air $62.83 -0.5 (-0.79%) ABT Abbott $75.14 -0.41 (-0.54%) CVS CVS Health $62.33 -1.86 (-2.90%) KALV KalVista $20.78 0.78 (3.90%) BCRX BioCryst $8.67 -0.33 (-3.67%) OPTN Optinose $7.29 0.08 (1.11%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb 22 Feb 27 Feb 28 Feb 04 Mar 04 Mar 07 Mar 11 Mar 11 Mar 12 Mar 18 Mar 19 Mar 22 Mar 28 Apr 13 May 18 May
MRK Merck $79.82 0.38 (0.48%) 07:28 02/22/19 02/22 07:28 02/22/19 07:28 Initiation	Merck initiated at Cantor Fitzgerald » Merck initiated with an… Merck initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Louise Chen started Merck with an Overweight rating and $95 price target. The company's sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as its margin expansion opportunities, are underappreciated at current share levels, Chen tells investors in a research note. She expects upward earnings revisions and multiple expansion in 2019 to drive Merck shares higher. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Apr 18 May 17 Jun
GSK GlaxoSmithKline $40.57 -0.193 (-0.47%) , RYCEY Rolls-Royce $0.00 (0.00%) 06:59 02/22/19 02/22 06:59 02/22/19 06:59 Hot Stocks	SFO ends investigations into Rolls-Royce and GlaxoSmithKline » The Director of the… The Director of the Serious Fraud Office announced the closure of the Rolls-Royce (RYCEY) and GlaxoSmithKline (GSK) cases. The investigation into Rolls-Royce PLC resulted in a Deferred Prosecution Agreement with the company and one of its subsidiaries in respect of bribery and corruption to win business in Indonesia, Thailand, India, Russia, Nigeria, China and Malaysia. Following further investigation, a detailed review of the available evidence and an assessment of the public interest, there will be no prosecution of individuals associated with the company. The GlaxoSmithKline PLC investigation focused on commercial practices by the company, its subsidiaries and associated persons. Again, following a detailed review of the available evidence and an assessment of the public interest there will be no prosecution in this case. Both cases were wide ranging and complex investigations, the SFO said. GSK GlaxoSmithKline $40.57 -0.193 (-0.47%) RYCEY Rolls-Royce $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	18 May
GSK GlaxoSmithKline $40.57 -0.193 (-0.47%) 05:36 02/22/19 02/22 05:36 02/22/19 05:36 Downgrade	GlaxoSmithKline rating change at UBS » GlaxoSmithKline… GlaxoSmithKline downgraded to Neutral from Buy at UBS. UBS analyst Laura Sutcliffe downgraded GlaxoSmithKline to Neutral and lowered her price target for the shares to 1,650p from 1,700p. Concerns around the company's HIV franchise are likely to keep a lid on the shares, Sutcliffe tells investors in a research note. Further, she believes consensus estimates for 2019 are "slightly too high." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	18 May

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial